Welcome to the Royal Philips Third Quarter 2015 Results Conference Call on Monday, the 26th of October, 2015. During the introduction hosted by Mr. Frans van Houten, CEO and Mr. Abhijit Bhattacharya, CFO, all participants would be in a listen-only mode. After the introduction, there will be an opportunity to ask questions. [Operator Instructions] Please note that this call will be recorded and is available by webcast on the Web site of Royal Philips. I will now hand the conference over to Mr. Robin Jansen, Head of Investor Relations. Please go ahead, sir.

Thank you, operator and good morning ladies and gentlemen. Welcome to Philips third quarter conference call. I'm here with Frans van Houten, CEO and Abhijit Bhattacharya, CFO, who took over from Ron Wirahadiraksa exactly two weeks ago. In a moment, Frans will make his opening remarks and will take you through our main strategic and financial highlights for the period. Abhijit will then provide more details on the financial performance during the quarter. After that, both Frans and Abhijit will be happy to take your questions. Our press release and the related information slide deck were published at 7:00 AM CET this morning. Both documents are now available for download from our Investor Relations Web site. A full transcript of this conference call will be made available by tomorrow on our Investor Relations Web site. Before I turn over the call to Frans, I would like to remind you of two things; following the decision in June 2014 to combine our Lumileds and Automotive Lighting businesses into a standalone company, the profit and loss of these combined businesses is reported under discontinued operations and the net assets for the business in the balance sheet on the line assets held for sale. The cash flow of the combined Lumileds/Automotive businesses is reported under cash flow from discontinued operations. Therefore, all commentary that will follow in terms of sales and earnings at both the group level, as well as the Lighting sector level excludes the performance related to the Lumileds and Automotive Lighting businesses; secondly, when we refer to adjusted EBITA on this call, this represents EBITA excluding restructuring costs, acquisition-related charges and other charges and gains above €20 million. With that, I would like to hand over the call to Frans.

Yes. Thanks, Robin. Good morning to everybody on the call. Before I begin to the Q3 performance, I’d like to take the opportunity to welcome Abhijit to his new role of CFO and provide you with a bit of background on the transition. Ron informed us shortly before the official announcement two weeks ago that he had decided to take on a new career challenge at LafargeHolcim, this came unexpectedly, but I'm glad that we were able to deal with this quickly. I'm happy with Abhijit taking the role as Philips’ CFO. Abhijit has built an impressive resume of delivering results in various financial and operational leadership roles at both Philips, as well as NXP. This together with his track-record of successfully managing highly complex projects will enable him to play a key role in advancing Philips’ transformation. I would also like to wish Ron all the best in his new role and I'm grateful for his substantial contributions to Philips. Now turning to the quarter. Our results continue to improve as good growth in Healthcare and Consumer Lifestyle and the year-over-year improvement in the operational performance in all three sectors. This was achieved despite continued foreign exchange headwinds and difficult microeconomic conditions in a number of the emerging markets, especially China, which demonstrate the resilience of our business and the progress that we're making on our transformation journey. And while we continue to make progress of our overall operational excellence the rest of the performance in certain areas and address our cost structure, we are making target investments in innovation to enhance our leadership positions. I will talk more about these investments in a moment when I discuss our third quarter performance in each sector. Let me now start with Healthcare, where we are very encouraged by continued sales…

Thank you, Frans. Good morning and welcome to all of you on the call. I'm honoured to join the top team at Philips at a very exciting time for the Company as we continue our transformation. I'd like to thank Ron for his guidance as we work together to ensure a seamless transition. I'm also looking forward to reconnect with the financial markets as I take on my role as Philips’ CFO and I'm sure I'll meet with most of you in the coming months. Let me start by providing you some more detail on our financial performance for the third quarter and some market developments. Comparable sales in the third quarter increased by 2% to €5.8 billion compared to last year. On a nominal basis total sales increased by 12%, mainly driven by 9 percentage points of positive currency translation effects. Our mature markets’ comparable sales increased by 3%, driven by 5% in Western Europe, 1% in North America and 3% in other mature markets. Sector-wise in the mature markets, Healthcare and Consumer Lifestyle grew mid-single digit, while Lighting declined low-single digit. In our growth geographies, comparable sales remained stable in the third quarter with double-digit growth in countries like Poland, Indonesia, India and Mexico being offset by sales declines in countries like China, Russia and Brazil. Sector-wise in the growth geographies, sales growth was driven by mid single-digit sales growth in Consumer Lifestyle, which was offset by mid single-digit sales decline in Lighting and a low single-digit sales decline in Healthcare. Let's take a closer look at order intake now. Currency-comparable order intake increased by 2% year-on-year, as a result of high single-digit order intake growth in Western Europe and mid single-digit order intake growth in North America, which was partly offset by double-digit order intake decline in…

Thank you, sir. [Operator Instructions] Would you please limit yourself to one question with a maximum of one follow-up, this will give more people the opportunity to ask questions. [Operator Instructions] We will now take our first question from Gaël De Bray from Societe Generale. Please state your question. Gaël De Bray: Two quick questions please. Could you elaborate it more on what's going on exactly with the Lumileds transaction? What are the issues there and netting relation through that and with the closing of the Lumileds transaction now what’s your plan? How does it affect the timing of your M&A strategy? So, that's one of the first question, the second question relates to the Consumer Lifestyle division, how do you explain the strong increase in working capital of the year? Is there an issue in terms of collective payments? Or have you changed somewhat the business for that sort of division?

Frans here let me take the first and then look to Abhijit to answer the question around the increase in working capital at Consumer Lifestyle. It is customary in the United States to request for a regulatory approval, the CFIUS committee looks at all foreign investments in the United States. Together with Go Scale Capital, we have applied for that approval. This is taking longer with some unforeseen concerns that we are working on in a collaborative fashion. As you will appreciate the CFIUS process is confidential and we are not at liberty to give you a peek inside of the dossier. So, let me not do that. We continue to work together on this towards a closing and that's what our focus is on. So, whereas we do flex on uncertainty, the main news here is also one of delay. There is no relationship at all with regard to the separation of Philips Lighting, this will underline that. And on your question on how this affects our M&A strategy, basically it does not change our M&A strategy. In any case we were cautious in our M&A approach and not in a hurry. We're making great progress in the implementation and aiming of Volcano where we are fully on schedule with our assumptions with regard to the benefits and integration. We have quite a lot on our plate with the separation of Philips Lighting and therefore we will not do anything unexpected on the M&A front. Strategically, we remain interested in bolt-on acquisitions as also elucidated with our capital markets there. And in the near-term there is no change in that outlook. Abhijit, the working capital question.

On working capital in CL it's really an issue on the Gregorian calendar we've moved this year to the Gregorian calendar. Last year we were not on it, so certain payment runs happen before the 31st of the month. So, if our receivables and our inventories are fine, it's actually timing on payables and that basically evens out through the year. So, it's not just for CL, it runs across all businesses but that's the main reason why you see that happening. Gaël De Bray: Can I have a quick follow-up on the Lumileds transaction? I can see the underlying performance for Lumileds is sharply down this quarter compared to a year earlier. Did you confirm that Go Scale is still very committed to the transaction?

Those parties work together all towards a closing, so no change.

We will now take our next question from Daniela Costa from Goldman Sachs. Please state your question.

So, two points, the first one just on, can you comment on so the Imaging all those having turned into growth? How much of that is recovering maybe market share that there was lost throughout the Cleveland closure versus underlying market getting better? And then the second thing, just on margin and on the operational improvement that you guide for 2015 I believe earlier in the year you had commented a while back of 100 basis points and at the capital markets say you’ve commented that, that was maybe tougher given the situation in the markets in effect, can you just give a little more of detail if possible? Thank you.

Yes. Good question on the over side and clearly we are very-very pleased with the order intake in United States at 5% and Europe even higher than that. After all these are our core markets and the high order intake is a clear sign of strength of our portfolio. Now if you dig a little bit deeper in that then I can tell you that the order recovery is pretty much across the board and our ultrasound is doing great, our patient monitor is doing well, you see several of the so called large iron image modalities doing good, we see MR having good strong traction, new orders on CT coming in. So, overall I see the Europe and United States trends as a very nice recovery without wanting to cry victory because I think that would be the wrong message, we still have more work to do, but I find it very encouraging. Now the negative piece is of course China, where we saw a negative order intake growth versus last year and there we hope in the future to be to also get back into positive territory. And then on the question of margin improvement, we basically stick by the entire explanation we gave at Capital Markets Day and I see the third quarter improvement as a nice underlying proof point of the trajectory that we are on and now we will diligently work into the fourth quarter which of course is an important quarter for us, seasonally always big and we will remain on the trajectory that we set. Now talking about foreign exchange, we warned for that in London and it did come in quite negatively with 160 basis points negative, yet we were able to overcome it and I think that's the strength of the improvement program with Accelerate! that we're on which came in at 210 basis points, outpacing the currency issue altogether and on that path we aim to continue.

We will now take our next question from Andreas Willi from JPMorgan. Please state your question.

My question is on Healthcare. You mentioned the slightly slower recovery at Cleveland, if the AIMS failed to recover 175 million over the two years, so if there is a move from '15 into '16 for the remaining margin or profit recovery and maybe you could also give some indication on pricing of these new orders, overall the pricing and the earnings bridge this quarter wasn’t bad, but what do you see in the order intake in your effort to regain the share? Thank you.

Yes. Good question. We remain committed to the overall profitability improvement in Cleveland the 175 that you mentioned, but clearly it has slipped somewhat with now expecting 50 million to 60 million this year, which means that the step up needs to be bigger next year. We have no reasons to backtrack from that ambition on the contrary we feel that we're making good progress in the marketplace also with customers, also with new order intake and the cost of stepping up and improving the quality management system is at an elevated level and that elevated level is expected to continue into 2016 thereby putting some counter pressure on the profit improvement. And with regard to price erosion overall and I think you already alluded to it Andreas, we see the customary equipment price erosion which overall for Healthcare then results into 1% to 2% and I said in the past that for a selected modalities and selected customers, we can go a little bit more aggressive as we want to repair some of the pain that we have caused to those individual customers and their price erosion can be a little bit higher, but not to the degree that it impacts the overall average of the Healthcare margin evolution. Right so I think that's in the end what we need to keep in mind.

And the follow-up on pricing, I mean if you have these strong effects headwinds because of import into some of these emerging markets, other companies maybe not directly related to Philips but other companies seem to be reasonably successful in compensating that by price increases because competition has the same issues when they have to import, for example into Brazil or other markets. Is that pricing benefits at Philips as well but kind of have been offset with the overall negative pricing on the bridge or why are you not able to offset more of that effects headwind?

Now I think what to see overall in the FX situation is that we have sizable dollar cost and even though in the United States of course we see also the benefit in the top-line, but globally we have sizable dollar cost and especially versus emerging markets there we see the negative and we can now see coming through is the existing sales being under pressure and it's hard to hedge for that in emerging markets, because it's very costly. Of course as you point out that for future orders we will adjust our prices, but that’s in the order intake and that’s not yet in the sales. So there is a time lag when it comes to adjusting for currency effects. We will of course do everything you said in fact we will do more because we overall feel that our cost structure should be brought more in line with a natural currency basket. And this is something that Abhijit has jumped immediately on in his role as CFO maybe at one of the future events we can elucidate a little bit on how we’ll evolve our industrial footprint and cost base to get more to a natural hedging situation.

We will now take our next question from Ben Uglow from Morgan Stanley. Please state your question.

I have a couple of questions again on Healthcare, one was more specific and I guess one general. On the margin bridge the Cleveland impact is minus one. And there are a lot of numbers flying around about what Cleveland was actually going to contribute this year, but my understanding on what I thought it was going to do this year was ballpark 80 million something like that 80 million to 100 million. I don't know if that’s correct. But maybe it’s more for Abhijit, but can you just tell us what is leading to the negative impact in EBITDA bridge this quarter? Is it simply quality investments, quality control or are there other factors at play? So can we have some specific understanding of that number in the margin bridge? And the second issue that I guess is maybe for Frans is more general, when we look into the fourth quarter it's normally your big quarter in Healthcare. If we go back historically, we’re normally looking at roughly a 3 percentage point margin step-up between the third quarter and the fourth quarter. When we look at 2015 and everything that’s happened what are the puts and takes on that step-up? What would make this a better or a worse year in terms of delivery in the fourth quarter?

Well since you directed questions so smartly to Abhijit then let's start with Abhijit.

On Cleveland the number I think which we have given out is 100 million improvement that we had planned on this year. We now say it’s going to be 50 to 60. So the 40 million gap largely comes Frans mentioned earlier that the ramp-up in Cleveland is going well. However, there are the smaller product lines which are delayed into next year, the remediation is delayed into next year, so we will have some loss of sales which of course then impacts the margin and the second one as you rightly pointed out is we have stepped up the remediation effort that we’re putting there and that results in slightly higher cost as well. So these are the two big ticket items that affect the 100 coming down to the range of 60 let’s say.

And just to be specific on that Abhijit, there is no significant negative price impact in that number. This isn’t an issue of you having to discount much more aggressively than you thought in order to re-launch Cleveland?

No, no, no, no. This is not linked and I think Frans mentioned it for specific customers who have been negatively impacted we may do something here or there, but that’s not a big impact on the overall numbers bringing the number down from where we said of 100 million to now the 60 million or so.

We will now take our next...

No, no, no, no. Ben had a second question operator and I'm sure he wants an answer on that. Well Ben without trying to specifically guide for the quarter which we don't do, I don't mind giving you a bit of color on it. And we saw of course in the third quarter a significant positive impact from our Accelerate! program and operational improvements and that will expectedly continue. We also expect a positive volume impact in the fourth quarter, and while seeing similar headwinds to a degree. Overall, we should expect a strong fourth quarter momentum. Yes what do you want to say about FX Robin?

Yes and as I think we expect additional tailwind from FX in the fourth quarter as well.

Okay, okay. A tailwind from FX?

Yes a small tailwind sort of because the U.S. revenue side in the fourth quarter is due to seasonality very big and so whereas we earlier in the call talked about being long on dollar cost long on dollar revenue and that spins that currency negative which was sizable in a small currency positive.

And again the same question Frans as well as Abhijit, we are not going to have to be absolutely crazy on price discounts to build up that order book in 4Q?

We don’t do anything crazy Ben you know us, right.

We will now take our next question from Daniel Cunliffe from Liberum. Please state your question.

Just a quick follow-up on the pricing. You talk about 2.2% or 140 million those similar to Q2. Just really wanted a bit more color on that. So you talked about no real aggressive price pressure in Healthcare. It just seems, if do you have any sort of color on the Lighting portion of that given the increased proportion of LED within that? And I am assuming that the overall consumer is flat to moderately up. Just give us sort of a bit of color on the pricing. And I just have a quick follow-up perhaps on the Healthcare Informatics the double-digit order decline given sort of mid to low single-digit growth in elsewhere within Healthcare, I was just wanted to get a sense a bit what’s behind that sort of double-digit pressure? Thank you.

All right, thanks. Well first, indeed confirm that on the consumer side we generally do not see price pressure because the rate of introduction of new products is so good that we are compensating and therefore we only see margin expansion in consumer, did really well down there. And in Lighting on the -- let's make a distinction first between the LED lamps and the LED luminaires. And overall in LED lamps, price erosion must happen because LED lamps need to come into a price range where also consumers will see it as a stable and start adopting it on a mass scale. We are getting very close to that and that price erosion on LED lamps has been double-digit for most of last year. In LED luminaires it’s actually the opposite. There we see margin expansion due to the functionality that gets into LED luminaires. Increasingly you see controls being embedded creating smartness in LED luminaires and we see prices typically being higher than in conventional lighting. This is also why in Abhijit’s part of the speech we elucidated that the conventional decline in the Professional Lighting Solutions side of the business is actually a good thing because it leads to margin improvement. If you add it all up, then we see a price erosion of around mid single-digit which is a stable situation all around. And then you have a question around Healthcare Informatics. I would like to bring to recollection that we had a double-digit order intake trend in the first half of the year and then in the third quarter it was negative. It reflects the lumpiness of that business and we actually believe that the business is on a upward trajectory overall, and very much benefiting from the leadership that is Jeroen Tas is giving to that business where we are moving it quickly into could-based environments as we see a lot of customer interest in our Healthcare Informatics solutions.

We will now take our next question from Philip Wilson from Redburn. Please state your question.

Just the first one is just coming back to your IGNS guidance of 450 million adjusted-EBITDA for the full year, so I think it still implies, that implies a very high fourth quarter cost above the seasonal norm. Can you comment on what the drivers are of this increase and is that 450 level we should expect in 2016, the first question. And secondly, on your R&D we saw a year-on-year increase of almost a point to the shared sales. Can you quantify what’s driving this, is it mix or are you seeing specific R&D increases in divisions, and should we expect this increase to continue? Thank you.

Hi, then let me take the one on IGNS guidance, you are right. It’s a bit heavily back-end loaded, a couple of reasons. One is of course the seasonality you know from the past, it’s between 40% and 45% in the first half and between 55% and 60% in the second half. This year it’s a little more back-end loaded for a couple of issues. One is, the license revenue that we expect in Q4 is slightly lower than what we had in Q4 last year. So that creates a bit of the gap, the normal seasonality as I mentioned. And then there are a couple of investments that we’ll kick in IT, you already saw a part of that in Q3, you will see a little more of that in Q4 as we get ready to launch out the Philips integrated landscape, which is the entire IT infrastructures that we are renewing so that is primarily the reason why it goes a bit higher in Q4. Regarding 2016, let me come back to you a bit later because we are going through our budgeting process et cetera and we will look at of course these costs very closely in the coming weeks, so I don’t want to guide at this stage but we will come back to you at a later stage.

All right then let's try to give a bit of commentary on the R&D, I think we have persistently flagged that in certain areas of the business we have increased R&D investments. This is related to Healthcare Informatics, personal health solutions and pathology, and what is also at play here is that we have cried a bit of R&D in dollars and the currency effect of course plays through in the R&D totals, and a part of our revenues is also in dollars but as earlier explained doesn't kept come in the same pace of increase as the cost stage that will reverse in the fourth quarter with the seasonality of sales more in dollars, so a bottom-line is yes R&D goes up a little bit, but certainly not the only reason for the percentage spike which is partially also currency related.

We will now take our next question from David Vos from Barclays. Please state your question.

Two questions from my side please, one on Lighting with the LED business now getting close to 50% of that business, I was wondering if you could give a rough spilt of how much of that business is professional and how much is consumer? And at the same time could you mention what the outlook for the EBIT trajectory is on the consumer side. I know that professional is doing much better there already, but I am really wondering with the size and the scale that Philips should have in a business already, where do you see margins end up overtime? So that’s question one. And then question two is on Respironics, really is a business we don’t speak too much about, but I was just wondering if you could give us a quick update on how you see the competitive landscape there developing. I think you mentioned something about new project launches there it will be interesting to hear if we're kind of in a similar gross margin range as your U.S. competitor there and how you think about that the growth going forward into this? Thank you very much.

Hi there, we need to do a little bit of work to have the consolidated spilt between consumer and professional of the LED business, so while that is being looked up. Operational performance was strong in LED lamps it was also strong in LED professional solutions and was still the weakest in the home part of the business where we still have more work to do. Looking at...

Yes so I think the consumer business would be about a quarter of the Lighting business and about 75% of it would be professional, which is the B2B part of the Lighting business.

Yes but that doesn’t yet answer how much of the consumer business is LED?

50.

Yes okay all right...

That was the missing piece of the puzzle now with joint effort here in the team, so summarizing 26% of Philips’ Lighting is consumer and 50% of that is LED and 50% is still conventional, reflects basically is in line with what we have talked about in general.

Sure.

And then the profitability of the business is higher on the professional side than on the consumer side. Yes then Respironics, and I think we had a good run for the last year with increasing market share. A recovery on the mask side you will recall that our competitor was stronger in masks for many years. And we have brought out several new products in the market with masks that has a very nice patient facial fit, and also breakthrough form factors as a consequence we are very excited about market share gains in that business. In the speech we were referring to sleep and respiratory care, Respironics is the dream product range which is a breakthrough product range for patients with sleep apnea challenges. This is a collective product, so besides the physical patient interface there is also a coaching app and remote assistance through the cloud, it's one of the businesses that has moved first towards the health free digital platform. Overall, we are very enthusiastic about our Respironics business even as the industry landscape especially in the United States is changing with regards to some reimbursement changes. Nevertheless, we continue to see good growth, good profitability expansion and market share gains.

And a glance on the gross margin there? Is that possible to share?

No, we usually do not break that out by business. Sorry about that.

We will now take our next question from Fredric Stahl from UBS. Please state your question.

Looking at Healthcare and the difference between orders and your revenue growth over the last few years and quarters, is it fair to assume that your order backlog is lower today than it has been for post-crisis and that hence you're more dependent on order wins over the next few quarters to deliver revenue growth? Is that correct?

I think generally that is correct. It has been stable actually over the last five quarters. Abhijit, do you want to say anything about it?

Yes, actually if you see Fredric in our booklet on Page 57, we give the position of the development of the order book and you clearly see that when the order intake was a little bit lower in Q4 and Q1 it went slightly down, but we are now building up pretty nicely. So, if you compare Q3 this year to Q3 next year, we're at similar levels now.

We will now take our next question from Alfred Glaser from Oddo Securities. Please state your question.

I wanted to get back to Cleveland. Could you give us a bit more color on how the Cleveland ramp-up has influenced order intake in Healthcare in Q3? And then I had a second question on Lighting. Could you comment a bit on the margin improvement or evolution in the LED space overall? And maybe give us some color on whether the lamps or the other parts of the LED business are even making better progress in terms of profitability?

Yes, sure, let's start with the order intake on the imaging side and which was a strong positive, certainly above the average for Healthcare and that is very much related to the recovery in diagnostic imaging. So, basically underlining the fact that we are on the right path in repairing and restoring our position and much of that order intake also came out of United States which of course makes us happy because it kind of says that the confidence in the market where Cleveland was the most visible is coming back. And with regard to your second question, margin evolution comes across the board in LED and this is good news, I already elucidated that in Professional we see -- we are in fact very happy with the move from conventional to LED because in LED we can build in all sorts of smart controls and features that make the overall price points higher and also the sales levels higher, the gross margin in Professional LED are already above average for the totality of Lighting. Now in LED lamps, which was arguably more of the battlefield for the last few years we saw significant price erosion, but also in LED lamps the margins are improving already for the last five quarters or so and start to contribute to the overall result. So, we are now at a stage where we can say comfortably that we believe that the profit pool in LED will be attractive and that we should be seeing a sustainable profitability level above from where Philips Lighting is today also when we make a complete move over to LED. Right so, Philips Lighting is not only having the leadership in conventional but clearly demonstrates also margin leadership in LED.

Unfortunately we only have time left for one more question. Our last question comes from Max Yates from Credit Suisse. Please state your question.

Just on the competitive landscape in Healthcare and I think across a number of players, we've heard various reports of some being more aggressive and competition stabilizing in China, and also some Japanese players being more aggressive at times. Could you give just an idea of how you're seeing your competitors in Asia behaving at the moment? Thank you.

Yes, everything that you said is true. We see that the Chinese trying to establish themselves although that's mostly in china itself at this moment we flag that, that's also through some local preference that gives these guys a little bit of wind in there, a little bit of tailwind. Our response of course is to continue to innovate for example our ultrasound with an anatomical intelligence build in that's a kind of clinical disease and support that our competitors don't have and it sets us apart. I can also confirm the aggressiveness on the Japanese side, it’s very much helped by the Japanese yen and devaluing versus the U.S. dollar and that gives an impetus of more export from Japan into the United States, whereas most of our production happens in the United States itself, and therefore we don't have any currency benefits with regard to our industrial footprint. So, this is a I guess a new reality where we see some more activity on the Japanese side, again there our response is innovation next to the large scale deals, because many of the Japanese competitors only have single products, can only compete on single modality deals whereas as you know we have a strategy around systems integration and winning large scale deals where for some of these competitors is more difficult to follow.

And just a follow-up on the Volcano business obviously within Image-Guided Therapy there is a 17% margin target I think by 2017. How is Volcano’s margin specifically expected to evolve within this and should this business be profitable this year sort of having come from obviously a loss in 2013?

Yes that margin goal that stands and of course is the blend between the equipment business and the catheter business coming from Volcano. I can report to you that Volcano is nicely on schedule. We do have this year the, what we call the post-merger integration cost, as well as we have the depreciation of intangible of the acquisition assets or at least a part of that. Operationally Volcano is doing very well and is improving its profitability as we speak. Also on the sale synergy side we see nice synergies in cross-selling between the two salesforces and that basically underlines our working assumptions when we did the deal. So, we're on-track and we don't breakout Volcano's profitability specifically, but with this color I hope that you can form a picture that we're quite pleased with this acquisition.

Thank you Mr. van Houten and Mr. Bhattacharya. That was the last question, please continue.

All right, well thanks everybody for dialling into this call. I hope that we've given you a good insight on how we are progressing. We are very pleased with the operational results improvement and we'll continue on that path forward. Thanks.